1 / 5

Allen J. Taylor et al. Circulation 2004; 110: 3512-3517

Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin. Allen J. Taylor et al. Circulation 2004; 110: 3512-3517.

rachel
Download Presentation

Allen J. Taylor et al. Circulation 2004; 110: 3512-3517

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110: 3512-3517

  2. Comparison of Baseline and 12-Mo Serologic Results for Patients Completing the Study Who Were Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110: 3512-3517

  3. Serial HDL-C during the 12-month study period for subjects in the placebo and extended-release niacin groups Allen J. Taylor et al. Circulation 2004; 110: 3512-3517

  4. Serial mean CIMT measurements from the far wall of the bilateral common carotid arteries at baseline and 12 months during treatment with either placebo or extended-release niacin (Niaspan) added to stable statin therapy Allen J. Taylor et al. Circulation 2004; 110: 3512-3517

  5. Change in IMT across 12 months in patients treated with placebo and extended-release niacin in presence or absence of metabolic syndrome or type 2 diabetes mellitus Allen J. Taylor et al. Circulation 2004; 110: 3512-3517

More Related